<SEC-DOCUMENT>0001193125-19-095742.txt : 20190402
<SEC-HEADER>0001193125-19-095742.hdr.sgml : 20190402
<ACCEPTANCE-DATETIME>20190402171032
ACCESSION NUMBER:		0001193125-19-095742
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20190402
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190402
DATE AS OF CHANGE:		20190402

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIO-RAD LABORATORIES, INC.
		CENTRAL INDEX KEY:			0000012208
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				941381833
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-07928
		FILM NUMBER:		19726168

	BUSINESS ADDRESS:	
		STREET 1:		1000 ALFRED NOBEL DRIVE
		CITY:			HERCULES
		STATE:			CA
		ZIP:			94547
		BUSINESS PHONE:		5107247000

	MAIL ADDRESS:	
		STREET 1:		1000 ALFRED NOBEL DRIVE
		CITY:			HERCULES
		STATE:			CA
		ZIP:			94547

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIO RAD LABORATORIES INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d721611d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report:&nbsp;April 2, 2019 (Date of earliest event reported) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">BIO-RAD</FONT> LABORATORIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission
File Number: <FONT STYLE="white-space:nowrap">1-7928</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">94-1381833</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1000 Alfred Nobel Dr. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Hercules, California 94547 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(510) <FONT STYLE="white-space:nowrap">724-7000</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this
chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>ITEM&nbsp;5.02</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Appointment of New Principal Financial Officer</U>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;2, 2019, <FONT STYLE="white-space:nowrap">Bio-Rad</FONT> Laboratories, Inc. (the &#147;Company&#148;) announced the appointment by the Board of
Directors of the Company of Ilan Daskal as the Company&#146;s Executive Vice President and Chief Financial Officer (including as principal financial officer), effective April&nbsp;6, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Daskal has over 25 years of experience in senior financial roles. Prior to joining the Company, Mr.&nbsp;Daskal, age 54, was the Chief Financial
Officer of Lumileds, a global leader in advanced lighting technology, from May 2017 to January 2019. From 2015 through 2016, Mr.&nbsp;Daskal held multiple short-term Chief Financial Officer roles with private and public companies including Aricent
Inc., a global design and engineering company, Cepheid, a molecular diagnostic company, and SunEdison Inc., a renewable energy company. Prior to that, from 2008 to 2015, Mr.&nbsp;Daskal was the Executive Vice President and Chief Financial Officer at
International Rectifier Corporation, a leader in power management semi-conductor technology that was publicly traded until it was acquired by Infineon Technologies in 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company and Mr.&nbsp;Daskal entered into an employment offer letter providing for, among other things, an annual base salary of $500,000 per year and a
2019 target cash bonus under the Company&#146;s corporate incentive bonus plan of 65% of his eligible earnings, with this cash bonus to be <FONT STYLE="white-space:nowrap">pro-rated</FONT> based on his time in the position. Within thirty days of his
hire date, the Company&#146;s Board will grant Mr.&nbsp;Daskal 3,500 restricted stock units and 3,500 <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Mr.&nbsp;Daskal&#146;s employment with the Company is terminated by the Company without good cause, he will be entitled to a lump sum payment equal to <FONT
STYLE="white-space:nowrap">one-year</FONT> of his then current annual base salary, provided that he first enters into a full release of all claims in favor of the Company, its affiliates and their respective officers, directors and employees in a
form provided by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the employment offer letter entered into between the Company and Mr.&nbsp;Daskal is filed as an exhibit to this
report as Exhibit 10.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no arrangements or understandings between Mr.&nbsp;Daskal and any person other than the Company pursuant to which he
was appointed as Executive Vice President and Chief Financial Officer. There is no family relationship between Mr.&nbsp;Daskal and any director or executive officer of the Company or any person nominated or chosen to become a director or executive
officer of the Company. Mr.&nbsp;Daskal has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the press release announcing the appointment of Mr.&nbsp;Daskal is furnished with this report as Exhibit 99.1. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Retirement of Christine A. Tsingos</U>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the Company
previously announced, Christine A. Tsingos notified the Company on January&nbsp;2, 2019 of her plans to retire from her position as Executive Vice President and Chief Financial Officer. Ms.&nbsp;Tsingos and the Company have agreed that she will
retire from her position as Executive Vice President and Chief Financial Officer effective April&nbsp;5, 2019 but will continue to be employed by the Company until May&nbsp;10, 2019 to assist with the transition of matters to Mr.&nbsp;Daskal, the
Company&#146;s new Executive Vice President and Chief Financial Officer. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Item&nbsp;9.01</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Financial Statements and Exhibits.</B></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Exhibit&nbsp;No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d721611dex101.htm">Employment Offer Letter between the Company and Ilan Daskal dated March&nbsp;15, 2019 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d721611dex991.htm">Press Release dated April&nbsp;2, 2019 </A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SIGNATURES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">BIO-RAD LABORATORIES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">April&nbsp;2, 2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Timothy S. Ernst</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Timothy S. Ernst</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Executive Vice President, General Counsel and Secretary</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d721611dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g721611dsp04.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;15, 2019 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">llan Daskal </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1731 Juarez Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Los Altos, CA 94024 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear llan, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I am pleased to extend to you our written offer of
employment to join <FONT STYLE="white-space:nowrap">Bio-Rad</FONT> Laboratories as the EVP&nbsp;&amp; Chief Financial Officer reporting directly to Norman Schwartz, President&nbsp;&amp; CEO. In your new position, your
<FONT STYLE="white-space:nowrap">bi-weekly</FONT> salary will be $19,230.77, equivalent to $500,000 annually. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are eligible to participate in our
Corporate Incentive Bonus Plan (IBP) with a targeted bonus of 65% of your eligible earnings, payable in March 2020. Your bonus will be <FONT STYLE="white-space:nowrap">pro-rated</FONT> based on your time in the position. The terms and conditions of
the IBP are contained in the plan document which you will receive at a later date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will also be eligible to participate in the 2019 Stock Program. We
will grant 3,500 Restricted Stock Units and 3,500 Stock Options within 30 days of your hire date; this grant has an estimated target value of $1.2 to $1.5&nbsp;million, based on our share performance history. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If after you begin employment with <FONT STYLE="white-space:nowrap">Bio-Rad</FONT> your employment is terminated by
<FONT STYLE="white-space:nowrap">Bio-Rad</FONT> without good cause, you will be entitled to a lump sum severance payment equal to <FONT STYLE="white-space:nowrap">one-year</FONT> of your then current annual base salary provided that you first enter
into a full release of all claims in favor of <FONT STYLE="white-space:nowrap">Bio-Rad,</FONT> its affiliates and their respective officers, directors and employees in a form provided by <FONT STYLE="white-space:nowrap">Bio-Rad.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This offer is contingent upon your passing a background check and drug test prior to starting employment and entering into a mutual agreement to arbitrate
with the company. The type of information requested in the background check includes: education verification, previous employment verification, professional references, and criminal record check. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Bio-Rad</FONT> maintains a smoke-free and drug-free work environment. As such, our expectation is that you complete a drug
test within five days of this offer. Hire Right, our background screening provider, will contact you regarding a clinic location for the drug test. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Bio-Rad&#146;s</FONT> comprehensive benefits package provides you with a
variety of options that will help meet your needs. You will have up to 31 days from your start date to enroll in these benefits. If you wish to enroll your eligible dependents, you may be required to present evidence of your dependents&#146;
eligibility, such as a marriage certificate or birth certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please acknowledge your acceptance of this offer by March&nbsp;18, 2019. This offer is
null and void after this date. Once received, a &#145;Welcome to <FONT STYLE="white-space:nowrap">Bio-Rad&#146;</FONT> letter will be <FONT STYLE="white-space:nowrap">e-mailed</FONT> with details regarding your
<FONT STYLE="white-space:nowrap">on-boarding</FONT> processes and a &#147;tentative&#148; new hire orientation date. <B><I>Please note that an official start date can&#146;t be determined until your background has cleared.</I></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For over 60 years, <FONT STYLE="white-space:nowrap">Bio-Rad</FONT> has benefited from the contributions of exceptional people like you. We seek the best
talent to build on the success of our Company and we look forward to you joining our highly collaborative environment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Colleen Corey</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Colleen Corey</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SVP, Global Human Resources</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="white-space:nowrap">Bio-Rad</FONT> Laboratories</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I accept <FONT STYLE="white-space:nowrap">Bio-Rad</FONT> Laboratories&#146; offer of employment as herein described. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ilan Daskal</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD ROWSPAN="2" VALIGN="top"></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;3/15/2019</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD ROWSPAN="2" VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>d721611dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Press Release </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Bio-Rad</FONT> Names Ilan Daskal Executive Vice President and Chief Financial Officer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>HERCULES, California. &#151; April</B><B></B><B>&nbsp;2, 2019</B> &#151; <FONT STYLE="white-space:nowrap">Bio-Rad</FONT> Laboratories, Inc. (NYSE: BIO and
BIOb), a global leader of life science research and clinical diagnostic products, today announced that the appointment of Ilan Daskal as Executive Vice President and Chief Financial Officer, effective April&nbsp;6, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Daskal comes to <FONT STYLE="white-space:nowrap">Bio-Rad</FONT> from Lumileds, where he served as Chief Financial Officer. He has over 25 years of
experience in senior financial roles and has held several CFO positions at both public and private companies that include International Rectifier Corporation and Infineon. Mr.&nbsp;Daskal holds a Masters in Finance degree from City University of New
York and a BB in Accounting from <FONT STYLE="white-space:nowrap">Tel-Aviv</FONT> College of Business in Israel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Ilan brings a breadth of
experience in finance, operations, IT, as well as mergers and acquisitions, all in a global setting,&#148; said Norman Schwartz, <FONT STYLE="white-space:nowrap">Bio-Rad</FONT> President and CEO. &#147;We believe he will make an excellent addition
to <FONT STYLE="white-space:nowrap">Bio-Rad.&#148;</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">Bio-Rad</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Bio-Rad</FONT> Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad
range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are
university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, <FONT
STYLE="white-space:nowrap">Bio-Rad</FONT> is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. <FONT STYLE="white-space:nowrap">Bio-Rad</FONT> had revenues exceeding $2.2&nbsp;billion in
2018. For more information, please visit <FONT STYLE="white-space:nowrap">www.bio-rad.com.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This release may be deemed to contain certain
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding the expected contributions and benefits of the new
officer. We have based these statements on the information now known to us. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements.
For further information regarding our risks and uncertainties, please refer to the &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operation&#148; in
<FONT STYLE="white-space:nowrap">Bio-Rad&#146;s</FONT> public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and our Quarterly Reports on Form <FONT
STYLE="white-space:nowrap">10-Q.</FONT> The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. <FONT STYLE="white-space:nowrap">Bio-Rad</FONT>
Laboratories, Inc. disclaims any obligation to update these forward-looking statements</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Press Contact</B>: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Bio-Rad</FONT> Laboratories, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tina Cuccia, Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">510-724-7000</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">tina_cuccia@bio-rad.com</FONT>
</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g721611dsp04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g721611dsp04.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MOV/BW1[^01I<>7(3@+(NW)^O2FI)E*K%Z&Y5&@4 % !0 =* "@ H * "@ H
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ME $]OJ\LLOEO;B/$HC)+$=0N." >K8Z=O<4 :U !0 4 % !0 4 % !0 4 %
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MYQ[JP]\<4 3G4[,$#SP<C/ )P, Y/IU'YB@"W0 4 % !0 4 % !0 4 % !0
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M3KAC0 ^XT2&X;?YKH^7^8*I.&QGJ#_=&/I0 U;>PLKV)7OPK1EFC@>10!O\
M;KZX^M !<:/9-%'YTKJ(YVFW%P"2S%BI/IG''^R/2@".+2+=MGE:C,\L&T!M
MR$H IP,;<=&)Z>GH* %/ART_>!9)%$B;6^[D_+MSG&0<?A0!=N+07;I)%=20
ME R9BV]R,CD'TH K1:?86US'"L^)0PE$;."2 I7H>2.2?KDT 0_V;I=DD.^[
M6,0XC)D9/F[@$D=<>F.* -9KB", O,B@J7&6 RHZGZ<C\Z '0S13QB2&5)$/
M1D8$?I0 ^@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M IJ*1HH1CL;546% !0 4 % !0 8H * "@ Q0 4 % !0 4 % !0 4 % !0 4
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M]: +T.G7D>HS7<EQ%*6C*Q_(5(R>AY/  7MZT :<48BC5 2<#J>I]Z 'T %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MKJ M(@CD5MK*">#^(!H M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 5&TZ!K6.W&Y4C;>I!Y!SU_4T 10Z1;6X'EM*&"% V\
MY"GMG]: )[JRBO %E+@<@A6(W ]0?44 )-I\$Z,KJPR5.58@@J<@CTH 7[!;
M_8C:;/W)&",\GG)R>^><_6@ ?3[22YCN6MXS,AW!]HSG&.OT- #TMHHX6B5
M$8L2/]XDG]2: *G]B61P2LA<$'S/.??P"/O9SC#'\Z ''1[/)(1U'&%61@%(
M &0 < X YZT 6X8([=-D8(&<DDDDGU)/)H DH * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
44 % !0 4 % !0 4 % !0 4 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
